VIIBRYD
Pronunciation: vil-AZ-oe-doen


What it isSSRI with 5-HT1A partial agonism; depression.
Why this oneLess sexual dysfunction than a pure SSRI, with the 5-HT1A action built into one molecule rather than requiring buspirone alongside.
What limits itIt must be taken with food or absorption halves. Diarrhea and nausea; CYP3A4-dependent.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Major Depressive Disorder | adult | 10 mg QD x7d | 20-40 mg QD | 40 mg QD |
Titration Increase at intervals of ≥7 days
Renal Undefined
Hepatic Undefined
Available strengths
Pregnancy Third-trimester use may increase risk of neonatal PPHN and withdrawal; register in pregnancy registry
Lactation Undefined
Generic entry2019
⚠ BOXED WARNING
Legacy pregnancy categoryC
Defining liabilityGI adverse effects and serotonergic toxicity; interactions occur through CYP3A.
Provisional washout figures
Elevating mechanismSRI
Non-elevating action5-HT1A partial agonist
Exposure dependenceTherapeutic exposure; severe toxicity requires meaningful MAO-A inhibition
Washout BEFORE an MAOI14 days
Evidence confidenceHigh
InterpretationClinically significant SRI plus 5-HT1A partial agonism. A second SRI generally represents therapeutic duplication/additive adverse effects, not the classic life-threatening interaction.
Open Vilazodone in the interactive console ↗
